![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » VILDAGLIPTIN SHOWS ADVANTAGES OVER EXISTING DIABETES THERAPIES
VILDAGLIPTIN SHOWS ADVANTAGES OVER EXISTING DIABETES THERAPIES
September 26, 2005
Newly-released Phase III data for vildagliptin, the first of a new class of oral antidiabetic drugs known as dipeptidyl peptidase-IV (DPP-IV) inhibitors, show the drug improves on currently available therapeutic options in several respects. Its developer, Novartis, claims it also has the potential to prevent prediabetic patients developing Type 2 diabetes along with cardiovascular and metabolic complications of the disease. Available data show vildagliptin avoids the GI side effects of metformin, it avoids the weight-gain seen with thiazolidinediones, and it cuts insulin requirements by approximately half.
Data presented at a recent Novartis research and development meeting for analysts showed how vildagliptin is performing clinically in large studies. Previously-reported smaller Phase II studies have shown vildagliptin reduces HbA1c, improves insulin sensitivity and sustains insulin levels suggesting improvement in beta-cell function. Preclinical studies have shown the drug increases beta-cell mass.
In a 780-patient Phase III trial comparing it against the European gold standard treatment for Type 2 diabetes, metformin, vildapgliptin was better tolerated than metformin while achieving similar sustained reductions in HbA1c over one year.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct